UK Investigational New Drug Cdmo Market Size & Outlook

The investigational new drug cdmo market in UK is expected to reach a projected revenue of US$ 293.4 million by 2028. A compound annual growth rate of 7% is expected of UK investigational new drug cdmo market from 2022 to 2028.
Revenue, 2021 (US$M)
$182.7
Forecast, 2028 (US$M)
$293.4
CAGR, 2022 - 2028
7%
Report Coverage
UK

UK investigational new drug cdmo market highlights

  • The UK investigational new drug cdmo market generated a revenue of USD 182.7 million in 2021 and is expected to reach USD 293.4 million by 2028.
  • The UK market is expected to grow at a CAGR of 7% from 2022 to 2028.
  • In terms of segment, small molecule was the largest revenue generating product in 2021.
  • Large Molecule is the most lucrative product segment registering the fastest growth during the forecast period.

Investigational new drug cdmo market data book summary

Market revenue in 2021USD 182.7 million
Market revenue in 2028USD 293.4 million
Growth rate7% (CAGR from 2021 to 2028)
Largest segmentSmall molecule
Fastest growing segmentLarge Molecule
Historical data2018 - 2020
Base year2021
Forecast period2022 - 2028
Quantitative unitsRevenue in USD million
Market segmentationSmall Molecule, Large Molecule
Key market players worldwideLabcorp Holdings Inc, Charles River Laboratories International Inc, Cambrex, IQVIA Holdings Inc, Syneos Health, Lonza Group Ltd, Catalent Inc, Recipharm, Siegfried Holding AG, Thermo Fisher Scientific Inc

Other key industry trends

  • In terms of revenue, UK accounted for 4.3% of the global investigational new drug cdmo market in 2021.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
  • In Europe, Germany investigational new drug cdmo market is projected to lead the regional market in terms of revenue in 2028.
  • Germany is the fastest growing regional market in Europe and is projected to reach USD 380.0 million by 2028.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Investigational New Drug CDMO Market Scope

Investigational new drug cdmo market segmentation & scope
Small Molecule
Large Molecule
Bioanalysis and DMPK studies
Toxicology Testing
Pathology and safety pharmacology studies
Drug substance synthetic route development
Drug substance process development
Form selection crystallization process development
Scale-up of drug substance
Preformulation
Preclinical formulation selection
First in Man Formulation/ Process Development
Analytical method development / validation
Release testing of drug substance and drug product
Work up Purification Steps
Telescoping & Process Refining
Initial Optimization
Formal stability of drug substance and drug product
Cell Line development
Microbial
Mammalian
Others
MABs
Recombinant proteins
Others
Oral Solids
Liquid and Semi-solids
Injectables
Others
MABs
Recombinant proteins
Others
Small
Medium
Large
Biotech Companies
Others

Investigational New Drug CDMO Market Companies

Name Profile # Employees HQ Website

UK investigational new drug cdmo market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to investigational new drug cdmo market will help companies and investors design strategic landscapes.


Small molecule was the largest segment with a revenue share of 88.78% in 2021. Horizon Databook has segmented the UK investigational new drug cdmo market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2028.


  • UK Investigational New Drug CDMO Product Outlook (Revenue, USD Million, 2018-2028)
    • Small Molecule
    • Large Molecule
  • UK Investigational New Drug CDMO Services Outlook (Revenue, USD Million, 2018-2028)
    • Contract Development
      • Small Molecule
        • Bioanalysis and DMPK studies
        • Toxicology Testing
        • Pathology and safety pharmacology studies
        • Drug substance synthetic route development
        • Drug substance process development
        • Form selection crystallization process development
        • Scale-up of drug substance
        • Preformulation
        • Preclinical formulation selection
        • First in Man Formulation/ Process Development
        • Analytical method development / validation
        • Release testing of drug substance and drug product
        • Work up Purification Steps
        • Telescoping & Process Refining
        • Initial Optimization
        • Formal stability of drug substance and drug product
      • Large Molecule
        • Cell Line development
        • Process Development
          • Upstream
            • Microbial
            • Mammalian
            • Others
          • Downstream
            • MABs
            • Recombinant proteins
            • Others
    • Contract Manufacturing
      • Small Molecule
        • Oral Solids
        • Liquid and Semi-solids
        • Injectables
        • Others
      • Large Molecule
        • MABs
        • Recombinant proteins
        • Others
  • UK Investigational New Drug CDMO End Use Outlook (Revenue, USD Million, 2018-2028)
    • Pharmaceutical Companies
      • Small
      • Medium
      • Large
    • Biotech Companies
    • Others

Reasons to subscribe to UK investigational new drug cdmo market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UK investigational new drug cdmo market databook

  • Our clientele includes a mix of investigational new drug cdmo market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UK investigational new drug cdmo market , including forecasts for subscribers. This country databook contains high-level insights into UK investigational new drug cdmo market from 2018 to 2028, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UK investigational new drug cdmo market size, by product, 2018-2028 (US$M)

UK Investigational New Drug CDMO Market Outlook Share, 2021 & 2028 (US$M)

UK investigational new drug cdmo market size, by product, 2018-2028 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more